Molecular profile of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia patients. Real World data from Argentina and Uruguay.

LINCANGO YUPANKI, MARCO; ANDREOLI, VERONICA; GARCÍA RIVELLO, HERNÁN; ASINARI, MARIANA; JAUK, FEDERICO; BENDER, ANDREA; CATALAN, A; RAHHAL, MARILINA; GIERE, ISABEL; MELA OSORIO, MARIA JOSE; NAVICKAS, ALICIA B; GRILLÉ, SOFÍA; AGRIELLO, EVANGELINA; PERUSINI, MARIA AGUSTINA; CASTRO, MARÍA BELEN; ARBELBIDE, JORGE; BASQUIERA, ANA L; BELLI, CAROLINA B

Marseille

Congreso; 17th International Congress of Myelodysplastic Syndromes; 2023

MDS Foundation

Next Generation Sequencing (NGS) data is increasing its diagnostic and prognostic power as shown by theIPSS-M. However, its access in South-America is restricted because of the high-cost and reimbursementlimitations. We aimed to evaluate the NGS real-world data of MDS/CMML patients collected by the ArgentineNGS-working-group.Sequencing and clinical data from 182 patients (145-MDS and 37-CMML) treated in five medical centers fromArgentina and one from Uruguay, were retrospectively collected. A 0.05 VAF cutoff was applied and VUS were excluded. Statistical analyses were performed by R(v4.2.2) considering a P